Stockscreener 앱 받기
54.70
7.00%
3.58
시장 영업 전:
55.00
0.30
+0.55%
전일 마감가:
$51.12
열려 있는:
$51.27
하루 거래량:
703.90K
Relative Volume:
0.82
시가총액:
$1.11B
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-37.47
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
-3.87%
1개월 성능:
-5.15%
6개월 성능:
+524.43%
1년 성능:
+5,370%
1일 변동 폭
$51.26
$56.99
1주일 범위
$51.04
$59.23
52주 변동 폭
$0.432
$66.92
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
54.70 | 1.04B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11%Here's Why - MarketBeat
Rezpegaldesleukin Shows Promise for AD, Comorbid Asthma, With Jonathan Corren, MD - HCPLive
Published on: 2025-12-14 04:41:07 - moha.gov.vn
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5%Here's What Happened - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.5%What's Next? - MarketBeat
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Transformative Advances This Year and Beyond - Dermatology Times
Can Nektar Therapeutics Stock Recover If Markets Fall? - Trefis
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy - sharewise.com
Nektar Therapeutics $NKTR Shares Sold by 22NW LP - MarketBeat
Is Nektar Therapeutics (NKTR) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
Nektar Therapeutics gains amid takeover speculation - MSN
Nektar Therapeutics (NKTR) Price Target Increased by 14.31% to 109.43 - Nasdaq
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛
Will Nektar Therapeutics stock maintain dividend yieldOptions Play & Real-Time Volume Trigger Notifications - Newser
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterPortfolio Performance Summary & Weekly High Return Stock Opportunities - Newser
Will Nektar Therapeutics stock benefit from green energy trendsTrade Signal Summary & Daily Oversold Stock Bounce Ideas - Newser
How robust is Nektar Therapeutics (ITH0) stock financial positionAnalyst Upgrade & Risk Controlled Daily Trade Plans - Newser
How strong dollar benefits Nektar Therapeutics (ITH0) stockTrade Risk Assessment & Long-Term Safe Investment Ideas - Newser
NKTR SEC FilingsNektar Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Will Nektar Therapeutics stock benefit from upcoming earnings reports2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Is Nektar Therapeutics stock attractive for ETFs2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 7.5%What's Next? - MarketBeat
Colorectal Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeu - Barchart.com
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - The Manila Times
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors - GlobeNewswire Inc.
Latex Allergy Market Covering Prime Factors and Competitive - openPR.com
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade - Finviz
Nektar Therapeutics Reveals Promising Phase 2b Trial Results - MSN
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap UpShould You Buy? - MarketBeat
Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Jefferies Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Jefferies Raises Nektar Therapeutics (NKTR) Price Target to $121 - GuruFocus
Nektar Therapeutics R (ITH0.MU) Q2 FY2025 earnings call transcript - Yahoo Finance
Nektar Therapeutics CEO sells $119,795 in shares By Investing.com - Investing.com South Africa
Citi starts Nektar with Buy, opens ‘positive catalyst watch’ - TipRanks
Nektar (NKTR) Receives Buy Rating with Positive Outlook from Cit - GuruFocus
Citi Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Portland Topic NEKTAR THERAPEUTICS | News, Weather, Sports, Breaking News - KATU
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Nektar Therapeutics chief R&D officer sells $62,801 in stock By Investing.com - Investing.com Australia
Nektar Therapeutics CLO Wilson sells $34,196 in shares By Investing.com - Investing.com South Africa
Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire) - Aktiellt
Nektar Therapeutics chief R&D officer sells $62,801 in stock - Investing.com
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):